Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD2- targeted immunoliposomes: Antitumor effects

Journal of the National Cancer Institute

Volumn 92, Issue 3, 2000, Pages 253-261

  Pagnan, Gabriella ^a   Stuart, Darrin D ^b   Pastorino, Fabio ^a   Raffaghello, Lizzia ^a   Montaldo, Paolo G ^a   Allen, Theresa M ^b   Calabretta, Bruno ^c   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF ALBERTA   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GANGLIOSIDE GD2; IMMUNOLIPOSOME;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034594649     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.3.253     Document Type: Article

References (53)

1. Pritchard J. "Megatherapy" for advanced neuroblastoma - rationale and role. Eur J Cancer 1995;31A:134-6.
2. Niethammer D, Handgretinger R. Clinical strategies for the treatment of neuroblastoma. Eur J Cancer 1995:31A:568-71.
3. Bister K, Nunn M, Moscovici G, Perbal B, Baluda MA, Duesberg PH. Acute leukaemia viruses E26 and avian myeloblastosis virus have related transformation-specific RNA sequences but different genetic structures, gene products, and oncogenic properties. Proc Natl Acad Sci USA 1982;72:3677-81.
4. Gewirtz AM, Calabretta B. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 1988;242: 1303-6.
5. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991;88: 2351-5.
6. Alitalo K, Winquist R, Linn CC, de La Chapelle A. Schwab M, Bishop JM. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sei USA 1984;81:4534-8.
7. Griffin CA, Baylin SB. Expression of the c-myb oncogene in human small cell lung carcinoma. Cancer Res 1985:45:272-5.
8. Thiele CJ, McKeon C, Triche TJ, Ross RA, Reynolds CP, Israel MA. Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system. J Clin Invest 1987;80: 804-11.
9. Raschella G, Negroni A, Skorski T, Pucci S, Nieborowska-Skorska M, Romeo A, et al. Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines. Cancer Res 1992;52:4221-6.
10. Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997;24:187-202.
11. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996;2: 668-75.
12. Neurath MF, Pettersson S, Meyer zum Buchenfelde KH, Strober W, Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
13. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 1995;92:3318-22.
14. Crooke RM. Cellular uptake, distribution and metabolism of phopsphorothioate, phosphodiester, and methylphosphonate oligonucleotides. chapt 24. In: Agrawal S, Crooke ST, editors. Antisense research and applications. New York (NY): Springer-Verlag; 1998. p. 427-49.
15. Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci USA 1988; 85:7079-83.
16. Srinivasan SK, Iversen PI. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 1995;9:129-37.
17. Henry SP, Templin MV, Gillett N, Rojko J, Levin AA. Correlation of toxicity pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-I. Toxicol Pathol 1999;27:95-100.
18. Stein C, Cheng YC. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?. Science 1993;261:1004-12.
19. Corrias MV, Guarnaccia F, Ponzoni M. Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules. J Neuro-Oncol 1997;31:171-80.
20. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, De Dionisio L, et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995;95:1814-23.
21. Bennet CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK. Cationic lipids enhance cellular uptake activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41:1023-33.
22. Litzinger DC, Brown JM, Wala I, Kaufman SA, Van GY, Farrell CL, et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta 1996;1281: 139-49.
23. Trubetskoy VS, Torchilin VP, Kennel S, Huang L. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells. Biochim Biophys Acta 1992; 1131:311-3.
24. Thierry A, Dritschilo A, Intracellular availability of unmodified, phosphorothioated and liposoinally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 1992; 20:5691-8.
25. Stuart DD, Allen TM. Pharmacokinetics of pegylated liposomal asODNs. Proc Int Symp Control Rel Bioact Mater 1998;25: 366-7.
26. Stuart DD, Kao GY, Allen TM. A novel, long-circulating and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. In press 1999.
27. Allen TM, Mouse EH. Therapeutic opportunities for targeted liposomal drug delivery. Adv Drug Del Rev 1996;21:117-33.
28. 2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997;80:317-33.
29. 2 mAb ch14.18 in a phase 1 trial in neuroblastoma patients. Cancer Immunol Immunother 1995;41:331-8.
30. 2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47: 1098-1104.
31. 2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44: 5914-20.
32. 2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 1999;81:268-74.
33. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibody to the disialoganglioside GD, and GD, specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 1986;83:7983-7.
34. Luger SM. Phase II study of autologous bone marrow transplant using marrow treated with c-myb antisense oligodeoxynucleotide (LR-3001) in chronic myelogenous leukemia in chronic or accelerated phase. PQD Clinical Trial Abs.; Protocol IDs: UPCC-3492, NCI-H94-0532. Bethesda (MD): CancerNel™; last modified 1998.
35. Pagnan G, Candi G, Montaldo PG, Bado M, Chiesa V, Allen TM, et al. Apoptosis of human neuroblastoma cells induced by liposome-encapsulated fenretinide. J Liposome Res 1998;8:401-23.
36. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75.
37. 125I]metaiodobenzylguanidine to neuroblastoma and melanoma cells in vitro. J Liposome Res 1999;9:367-85.
38. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, et al. Differential effects of N-(4-hydroxyphenil)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55: 853-61.
39. Tondelli L, Ricca A, Laus M, Lelli M, Citro G. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res 1998;26:5425-31.
40. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmaco; Toxicol 1992;32:329-76.
41. Davis SS. Biomedical applications of nano-technoiogy - implications for drug targeting and gene therapy. Trends Biotechnol 1997;15: 217-24.
42. Zelphati O, Szoka FC Jr. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet? J Controlled Release 1996;41:99-119.
43. Li S, Huang L. Targeted delivery of antisense oligodeoxynucleotides formulated in a novel lipidic vector. J Liposome Res 1998;8:239-50.
44. Wargalla UC, Reisfeld R. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci USA 1989;86:5146-50.
45. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233: 134-44.
46. Ramsay G, Evan GI, Bishop JM. The protein encoded by the human proto-oncogene c-myc. Proc Natl Acad Sci USA 1984;81: 7742-6.
47. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995:1237:99-108.
48. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93: 14164-9.
49. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, Gurtner GC, et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci U S A 1997;65:491-7.
50. Lopes De Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58:3320-30.
51. Allen TM, Ahmad I, Lopes De Menezes DE, Moase EH. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem Soc Trans 1995;23:1073-9.
52. Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998;22:971-9.
53. Walker MJ, Silliman E, Dayton MA, Lang JC. The expression of c-myh in human metastatic melanoma cell lines and specimens. Anticancer Res 1998;18:1129-35.